2026 Taihu Bay Biomedical Industry Trade Fair: Capturing the Pulse of China's Biopharma Innovation

Source: Wuxi Daily

Wuxi in May witnesses a surging wave in the life health industry. Stepping into the Wuxi International Conference Center, one can see a series of precisely interconnected biopharmaceutical industrial chains unfolding before their eyes. On May 8, the 2026 Taihu Bay Biomedical Industry Trade Fair, themed “Healthy New Consumption, Industrial New Future,” opened here. Over 220 exhibitors, more than 1,000 industry leaders, and nearly 100 top fund companies gathered at the event. More than 40 professional conferences and thematic activities held concurrently turned the entire venue into a powerful industrial magnet.

Unlike the traditional "large and comprehensive" flat exhibition model, this trade fair focuses on three core tracks: innovative pharmaceuticals, medical devices, and high-end medical aesthetics. The exhibition hall is divided into multiple sections, including innovative pharmaceuticals, medical devices, healthy living, and achievements exhibition, and special zones such as brain-computer interface, cell and gene therapy, synthetic biology, nuclear medicine, Yangtze River Delta Dental Valley, cosmetics supermarket, and Taihu·Longsha Medical School Market have been set up. "One special zone represents one industrial chain" – this is the most intuitive feeling when visiting the exhibition.

Walking into the Cell and Gene Therapy (CGT) exhibition area, 13 high-quality enterprises, including Huatai Innovative Drug Technology Research Institute, Shengji Pharmaceuticals, and Spiman Biotech, are gathered here, outlining a clear path from basic research, technological breakthroughs to clinical transformation. The recently established Jiaheng Cell Preparation Center is also making its anticipated debut, showcasing its planned integrated preparation base in the East China region, which will be built with an investment of 1 billion yuan. The project covers the full range of cell, virus, and plasmid categories, with core technologies benchmarked against leading levels in China. Once completed and operational, the project is expected to generate an annual output value of over 700 million yuan. Here, capital and scientific research shake hands, and the laboratory is only separated from the market by a display board.

If the CGT exhibition area allows people to see the depth of the industry, the brain-computer interface exhibition area, which brings together 16 benchmark enterprises in the field of brain-computer interface from China and abroad, is a "science fiction scene" leading to the future. Huichuang Medical's near-infrared brain function imaging device solves the worldwide problem of imaging difficulty with Asian black hair using 157 ultra-high channel technology. The brain-computer interface hand function rehabilitation developed by SirremRobot, successfully obtaining the world's first Class III medical device registration certificate in this field, allowing高位截瘫 patients to control their fingers through "thought" and regain self-care ability. Companies such as Medtronic, Neuracle, and DeepBrain Medical have also brought cutting-edge products in the fields of neural modulation, brain signal acquisition, and clinical rehabilitation.

The Frontier Exhibition Area Measures the Height of the Industry, but the Longest Queue in the Venue that Day Appeared Elsewhere. At the Taihu Lake · Longsha Medical School Fair, crowds gathered in front of two "Longsha No. 1" robots. Independently developed by the City Hospital of Traditional Chinese Medicine, "Longsha No. 1" incorporates tens of thousands of classic medical cases from renowned doctors of the Longsha Medical School and diagnostic records from modern inheritors. By taking a photo of the face and tongue, and using a pulse diagnosis instrument to check the pulse, a detailed constitution identification and personalized conditioning plan is displayed on the screen just minutes later. Besides the Taihu Lake · Longsha Medical School Fair, the cosmetics supermarket located in the atrium of the International Conference Center is another area offering an intensive "New Health Consumption" experience. Over 100 international brands, emerging domestic trends, and brands incubated or collaborated with Jiangnan University—such as La Mer, Clarins, Deco, Spring Letter, and Koma—are displayed together, creating a new consumption scenario integrating exhibition, experience, trial, and purchase.

The "circle of friends" of this trade fair is also broad enough. Among the participating companies, there are not only international benchmarks such as AstraZeneca, GE Healthcare, and Pfizer, but also local leaders like Sinopharm Medical Devices, Quark Pharmaceuticals, and Zhiyuan Pharmaceutical. Additionally, there are rising stars in cutting-edge fields such as Genetron, Nova Tech, and Tianmu Biotech. At the same time, it gathers...Bank of China、Bank of Communications, Xichuang Investment and other financial institutions strongly support, precisely empowering industrial innovation and development with capital. The exhibition site also features a South Korean delegation, with Wuxi's sister city Chuncheon showcasing innovative companies such as VOTEM and Ustation, presenting multiple portable electronic medical devices that integrate South Korea's high-end electronic component manufacturing experience.

More notably, the trade fair is upgrading from a "display venue" to a "high ground of industry thought leadership." Relying on the biopharmaceutical industry foundation of Wuxi Taihu Bay, the trade fair collaborates with organizations such as the Chinese Biopharmaceutical Association (CBA) and Pharma Intelligence Network during the same period, establishing a dual-engine model of "industry exhibition + international annual conference." The CBA-China 2026 Annual Meeting will be held during the trade fair, featuring multiple high-end forums on vaccines/radiopharmaceuticals, nucleic acid drugs, small molecule innovative drugs, ADC fields, clinical trials, large molecule drugs, cell and gene therapies, global regulatory submissions and regulations, AI in pharmaceuticals, addressing industry pain points and cutting-edge directions. At the 2026 MDI-China Medical Device Innovation Cooperation Conference, the "2026 Medical Device R&D Power Ranking" and the "2026 Medical Device R&D Blue Book" will be released through the trade fair platform, constructing an entire industrial chain ecosystem loop from technology development, achievement transformation to market application.

A Successful Start, More Excitement to Come. In the upcoming days of the conference, more intellectual exchanges and industry alignments will take place on this vibrant land. From a single exhibition board to an entire industrial chain, from a specialized zone to an innovation hub, this trade fair has already captured the true "pulse" of the biopharmaceuticals industry — Wuxi is using it as a window to showcase to the world the thriving strength of China's biopharmaceuticals industry.

(Zhu Dongya)